LTR Pharma (ASX: LTP) Strengthens U.S. Commercial Push with Definitive Shed Agreement for ROXUS Launch

LTR Pharma (ASX: LTP) has moved another step closer to generating revenue in the world’s largest healthcare market after signing a definitive commercial agreement with U.S. telehealth company Shed to support the launch of its erectile dysfunction treatment, ROXUS.

The agreement converts the binding term sheet announced in June into a comprehensive long-form commercial contract, providing the legal and operational framework for ROXUS to be commercialised through Shed’s dedicated men’s health platform, Mavrox.

Perhaps the most significant detail is Shed’s commitment to support delivery of no fewer than 150,000 ROXUS units during the first 12 months after commercial launch. While this is not a guarantee of revenue, it provides one of the clearest indications yet of the expected scale of the product’s initial rollout.

Live stock: Source Tradingview

For LTR Pharma, the announcement signals a transition from clinical development toward commercial execution. Rather than investing heavily in building its own U.S. sales force, prescribing network and patient acquisition platform, the company is leveraging an established telehealth provider already operating in the rapidly growing digital men’s health market.

That strategy reflects a broader trend across healthcare, where smaller biotechnology companies increasingly partner with specialist platforms to accelerate market entry while limiting upfront costs and execution risk.

The U.S. men’s health market has expanded rapidly in recent years, led by direct-to-consumer telehealth providers that allow patients to access consultations, prescriptions and home delivery without visiting a clinic. Companies such as Hims & Hers and Ro have helped reshape how erectile dysfunction treatments are prescribed and delivered, creating an established pathway for new therapies.

LTR Pharma is positioning ROXUS as a differentiated option within that market. Unlike conventional oral medications, ROXUS is an intranasal treatment designed for rapid onset, offering an alternative for patients seeking faster-acting therapy. (Source: LTR Pharma ASX announcement.)

The agreement also builds on several milestones achieved by the company during 2026, including positive Phase II SPONTAN study results, clarification of its U.S. Food and Drug Administration pathway, the appointment of an exclusive U.S. pharmacy partner and ethics approval for its OROFLOW study.

Executive Chairman Lee Rodne said the agreement represented a major milestone in the company’s U.S. strategy.

“Executing this definitive agreement with Shed is a major milestone in our U.S. commercialisation strategy, and one we’re genuinely excited about. We’ve now moved from signing a binding Term Sheet to executing a definitive long-form commercial agreement with a partner that has built a highly capable direct-to-consumer telehealth platform. We believe this provides LTR Pharma with a credible, scalable pathway into the U.S. market.”

He added:

“Shed brings an established telehealth platform, a licensed prescriber network and real patient acquisition expertise, capabilities that would have taken us significant time and investment to build on our own. Combined with ROXUS’s differentiated, rapid-onset profile, we believe this partnership gives U.S. patients a genuinely differentiated treatment option and gives LTR Pharma a credible, scaled pathway into the U.S. market.”

“Our focus now turns to completing the remaining implementation activities alongside the Shed team and delivering Commercial Launch.”

Shed Chief Executive Officer Morley Baker said ROXUS would play a central role in the company’s men’s health offering.

“We’re thrilled to announce our formal partnership with LTR Pharma. ROXUS is a genuinely differentiated product in a category that has seen very little true innovation, and a rapid-onset intranasal option is primed for customer success.”

“Mavrox will launch with ROXUS as its hero product, furthering our commitment to supporting its successful commercial launch. Our teams are eager to bring ROXUS to patients across the U.S. alongside the LTR Pharma team.”

The focus for investors now shifts from regulatory and clinical milestones to commercial execution. Key developments to watch include the timing of the U.S. launch, patient uptake, repeat prescriptions and the company’s ability to expand distribution beyond its initial telehealth partnership.

While commercial success will ultimately depend on patient adoption and market competition, the definitive agreement reduces a significant layer of uncertainty by establishing the commercial framework ahead of launch and providing LTR Pharma with an experienced partner in one of the world’s most competitive healthcare markets.